Manual IVF Screening May Miss Additional Oocytes - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Manual IVF Screening May Miss Additional Oocytes

Clinical study suggests automated system can recover mature oocytes overlooked during standard screening

  • By

  • Henry Thomas

  • February 18, 2026

  • 3 min

Share

Objective:

To evaluate the effectiveness of an automated microfluidic device in recovering additional oocytes from follicular fluid during in vitro fertilization (IVF) and its potential impact on IVF outcomes.

Key Findings:
  • The FIND-Chip recovered at least one additional oocyte in over half of the cases, with one case resulting in a live birth from an additional oocyte that was previously discarded.
Interpretation:

The findings suggest that manual screening may overlook viable oocytes, and automated systems like FIND-Chip could enhance oocyte recovery, potentially improving IVF outcomes.

Limitations:
  • The study's findings were descriptive due to the small sample size of the pilot return cohort, limiting the ability to generalize results.
Conclusion:

Automated screening technologies may improve IVF laboratory efficiency and outcomes by recovering additional viable oocytes that manual screening may miss, highlighting the need for further research.

Sources:

Original Source(s)

Manual IVF Screening May Miss Additional Oocytes

  • by Henry Thomas

  • February 18, 2026

Related Content

Fertility Issues May Be Linked to Autism

In a nationwide US cohort, parental subfecundity was associated with higher odds of autism spectrum disorder and modest increases in behavioral symptoms, while in vitro fertilization showed no statistically significant associations with neurodevelopmental outcomes.

AI Falls Short on Differential Dx

New PrIME-LLM benchmark shows strong diagnostic accuracy but persistent gaps in clinical reasoning across 21 large language models

When Bad Data Enters the Drug Pipeline

Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.